Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Telix Pharmaceuticals Limited for possible securities fraud, potentially leading to a class action lawsuit on behalf of investors [1]. Group 1: Legal Actions and Investigations - The Portnoy Law Firm is encouraging investors to contact them to discuss their legal rights and options for pursuing claims to recover losses [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to the development of its prostate cancer therapeutic candidates [3]. - Following the SEC subpoena news, Telix's American Depositary Receipt (ADR) price dropped by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [3]. Group 2: Firm Background - The Portnoy Law Firm has a history of representing investors in claims related to corporate wrongdoing, with the founding partner having recovered over $5.5 billion for aggrieved investors [4].
Telix Pharmaceuticals Limited Investigated by the Portnoy Law Firm